Carl Zeiss Meditec Faces Dual Operational Headwinds

Carl Zeiss Meditec's Q1 EBITA plunges 77% as new US tariffs target its core medical devices, compounding market uncertainty and a steep share price decline.

The medical technology group Carl Zeiss Meditec is navigating a period of significant turbulence. The company's challenging start to its fiscal year, marked by a sharp decline in profitability, has been compounded by a new wave of U.S. tariff policies that directly impact its core product lines. This combination of internal and external pressures is straining the firm's financial performance.

First Quarter Earnings Collapse

Carl Zeiss Meditec's operational difficulties were laid bare in its Q1 2025/26 report. Group revenue contracted by 4.8% to 467 million euros. More alarmingly, the firm's earnings experienced a severe downturn. The operating result (EBITA) plummeted from 35.2 million euros to just 8.1 million euros. Consequently, the EBITA margin collapsed from 7.2% to a meager 1.7%.

Chief Financial Officer Justus Felix Wehmer attributed this weak start to the fiscal year to geopolitical uncertainties and a noticeable hesitancy among customers regarding capital expenditure decisions. Both of the company's strategic business units remained below prior-year levels.

New U.S. Tariffs Target Core Portfolio

Adding to these operational woes, a shift in U.S. trade policy presents a fresh challenge. Effective immediately, the U.S. government is imposing a 10% base tariff on non-pharmaceutical medical technology imported from the European Union. This policy directly affects key revenue drivers for Carl Zeiss Meditec, including surgical microscopes and medical lasers.

Market observers from Citibank note that the U.S. Department of Commerce is already reviewing additional sectors currently exempt from duties. The industry association MedTech Europe warns that such measures will increase margin pressure across the European medtech sector and lead to longer delivery times. Companies may be forced to redirect investments from research and development toward logistics and compliance.

China Uncertainty and Share Price Decline

Beyond the U.S. market, the crucial China segment remains a source of uncertainty for investors. The market is awaiting clearer data on consumer behavior within the refractive market and the results of national tenders for intraocular lenses.

This challenging fundamental picture is reflected in the company's share price performance. The stock has been in a established downtrend since June 2025, losing more than 56% of its value in that period. Most recently, on March 23, the shares hit a new 52-week low of 22.62 euros.

Path Forward Awaits

While Carl Zeiss Meditec is showcasing new digital and surgical solutions at the ASCRS conference in Washington starting Friday, a concrete operational response is not expected until May 12, 2026. On that date, management will present its half-year figures alongside an updated annual forecast. The company also plans to provide specific details of a restructuring program designed to halt the erosion of earnings.